To include your compound in the COVID-19 Resource Center, submit it here.

bluebird raises $600M on heels of ASH data

Cell therapy company bluebird bio Inc. (NASDAQ:BLUE) raised $600 million

Read the full 103 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE